90780-51-1 Usage
Uses
Used in Biomarker Applications:
(+/-)16-HDOHE is used as a biomarker for oxidative stress in brain and retina tissues. Its presence indicates the level of oxidative stress in these areas, which is important for understanding the impact of oxidative stress on brain and retinal health.
Used in Research and Diagnostics:
(+/-)16-HDOHE is utilized in research studies and diagnostic tests to assess the extent of oxidative stress in brain and retina tissues. This helps in identifying potential health risks and monitoring the effectiveness of treatments aimed at reducing oxidative stress.
Used in Pharmaceutical Development:
(+/-)16-HDOHE may be employed in the development of pharmaceuticals targeting oxidative stress-related conditions in the brain and retina. Its role as a biomarker can aid in the evaluation of drug efficacy and the development of novel therapeutic agents.
Used in Nutritional Studies:
(+/-)16-HDOHE can be used in nutritional studies to investigate the effects of diet and supplementation on oxidative stress levels in the brain and retina. This can help in formulating dietary recommendations and identifying potential nutritional interventions for maintaining brain and retinal health.
Check Digit Verification of cas no
The CAS Registry Mumber 90780-51-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,0,7,8 and 0 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 90780-51:
(7*9)+(6*0)+(5*7)+(4*8)+(3*0)+(2*5)+(1*1)=141
141 % 10 = 1
So 90780-51-1 is a valid CAS Registry Number.
90780-51-1Relevant academic research and scientific papers
OXYLIPINS FROM LONG CHAIN POLYUNSATURATED FATTY ACIDS AND METHODS OF MAKING AND USING THE SAME
-
Page/Page column 58, (2008/06/13)
Disclosed are novel oxylipins, referred to herein as docosanoids, that are derived from C22 polyunsaturated fatty acids, and method of making and using such oxylipins. Also disclosed is the use of docosapentaenoic acid (C22:5n-6) (DPAn-6), docosapentaenoic acid (C22:5n-3) (DPAn-3), and docosatetraenoic acid (DTAn-6: C22:4n-6) as substrates for the production of novel oxylipins, and to the oxylipins produced thereby. Also disclosed is the use of DPAn-6, DPAn-3, DTAn-6, and/or the oxylipins derived therefrom, and/or novel docosanoids derived from the structures of C22 fatty acids, in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. The invention also relates to novel ways of producing long chain polyunsaturated acid (LCPUFA)-rich oils and compositions that contain enhanced and effective amounts of LCPUFA-derived oxylipins, and particularly, docosanoids.
